Drug and disease signature integration identifies synergistic combinations in glioblastoma

Glioblastoma (GBM) is the most common primary adult brain tumor. Despite extensive efforts, the median survival for GBM patients is approximately 14 months. GBM therapy could benefit greatly from patient-specific targeted therapies that maximize treatment efficacy. Here we report a platform termed S...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Nat Commun
Main Authors: Stathias, Vasileios, Jermakowicz, Anna M., Maloof, Marie E., Forlin, Michele, Walters, Winston, Suter, Robert K., Durante, Michael A., Williams, Sion L., Harbour, J. William, Volmar, Claude-Henry, Lyons, Nicholas J., Wahlestedt, Claes, Graham, Regina M., Ivan, Michael E., Komotar, Ricardo J., Sarkaria, Jann N., Subramanian, Aravind, Golub, Todd R., Schürer, Stephan C., Ayad, Nagi G.
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6294341/
https://ncbi.nlm.nih.gov/pubmed/30552330
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-018-07659-z
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados